Characterisation

Get In Touch

Product specifications are only as good as the analytical methods used to define them. We’re experts in developing strategies and supporting assay development, qualification and validation. We’re also highly experienced in the demanding potency assays required for complex biopharmaceutical products.

 

Failure to adequately demonstrate comparability can be a common reason for regulatory non-acceptance. Our consultants can help design required comparability studies to satisfy regulators’ expectations: for changes to your manufacturing process as you optimize it along the way; for biosimilars requiring high precision; or for products with very high intrinsic variability such as autologous cell therapies.

 

Helping you stay one step ahead of change

 

Comparability is a major–and very common–challenge for developers of biopharmaceuticals. Changes to the manufacturing process take place almost invariably during product development. These might be major changes within the manufacturing platform and/or changes to the manufacturer itself. Our experienced professionals will ensure that nothing is left to chance in our assessment of the impact of these variances and their reporting to regulators.

 

Get In Touch

Insights Hub

Sharing insights, questioning norms, asking the right questions - we'll never lose sight of what you're striving for. Our insight and expertise will help you bring the most innovative therapies within reach of patients around the world.
Placeholder Image
28.06.23
Steve

Cell & Gene Therapy: Maximizing Commercialization Potential

How to Navigate the Less Obvious Barriers to Brining Advanced & Highly Targeted Treatments to

Start a conversation today

If you’re developing something truly ground-breaking, Biopharma Excellence is the nearest resource you’ll find to someone who’s been there before.

Socials:








    We are now Cencora PharmaLex 

    PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

    Know more